In this episode of Raise the Line, we dive into the fascinating story of a very old technology, EEGs, being mined for data using a very new technology, AI, that's changing the way treatments are being developed for disorders of the brain. Joining host Michael Carrese to explain is Dr. Jake Donoghue, co-founder and CEO of Beacon Biosignals, a startup that’s using AI to unlock precision medicine for various neurological, psychiatric and sleep disorders. “We utilize our AI tools to bring quantitative endpoints into clinical trials to see if the drugs are impacting brain activity,” Donoghue explains.  AI’s ability to quickly recognize subtle changes in electrical activity that might otherwise go unnoticed can accelerate the trial process and hopefully, approval of new therapies. Donoghue is also interested in the area of sleep medicine because of its connection to a wide variety of issues including depression, PTSD, Parkinson’s and Alzheimer’s disease. “We think there's a lot of opportunity to bring quantitative insights to this fundamental state that all humans go through and map some of these really robust features of brain activity to increase understanding of disease and health.”

Mentioned in this episode:  https://beacon.bio/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

If psychedelics are eventually authorized by the FDA for use in mental health treatment, much credit will go to The Johns Hopkins Center for Psychedelic and Consciousness Research which sparked a renaissance of interest in the compounds starting in 2006 under the guidance of Dr. Roland Griffiths. The first study was actually not about clinical applications of hallucinogens but rather it observed their impact on healthy people. “One of the most remarkable findings Roland Griffiths encountered early on was that people would endorse the statement that they had one of the top five or the single most personally meaningful and spiritually significant experiences of their lives,” says Associate Center Director Dr. Fred Barrett, who met host Shiv Gaglani in his office in Baltimore for this extended conversation. And while the Center is actively researching potential clinical use of psychedelics, which is promising, it remains interested in how they may improve the lives of those not in need of mental health treatment. “What are the opportunities for spiritual growth? What are the opportunities for increasing well-being? There's an opportunity for exploration here that, if we're very careful, may have utility and value outside of the medicalization of these compounds,” adds Barrett. Don’t miss this expansive (dare we say mind-expanding?) discussion of the possible reasons psychedelics may help people with depression, why they are not prone to misuse, and what they tell us about the nature of consciousness itself. 

Mentioned in this episode: https://hopkinspsychedelic.org/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“The unifying theme across our portfolio is that whatever a company we invest in is building can make a population-level health impact. For us, that means that what they're doing is going to lead to innovation that is ultimately accessible to huge portions of the global population,” says Gurdane Bhutani, co-founder and managing partner of MBX Capital, a venture capital partnership dedicated to investing in early-stage companies focused on big public health problems. As he explains to host Shiv Gaglani, that ambitious mission is focused on three main themes: accumulated environmental exposure (exposome), biosecurity and biodefense, and healthcare infrastructure. “The majority of disease pathogenesis today is environmental in nature, not genetic. So we're looking at companies that are developing exposomic sequencing technologies that help us better understand these environmental exposures.” One such company is using human-relevant tissue models to test for environmental contaminants. Others include a nurse scheduling platform and a firm that’s localizing radiology systems for underdeveloped areas. Bhutani has a track record of investing in interesting and impactful companies in healthcare (in fact, he was an early backer of Osmosis!) so you won’t want to miss his insightful perspective on promising ideas for improving health and healthcare systems.

Mentioned in this episode: https://www.mbxcapital.com/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

One challenge in developing treatments for rare diseases is finding enough people with the condition to mount valid clinical trials.  Databases that contain diagnostic codes for specific conditions can help, but those miss people who may have the condition but have yet to be conclusively diagnosed.  That’s where Verana Health comes in, a digital health company that uses AI to mine its data network of more than 20,000 healthcare providers and the clinic notes they make about patient encounters. “If you wanted to find somebody with a specific genetic defect, or a specific condition for which a diagnostic code doesn't even exist, clinic notes represent really the only place you could discover that information,” explains Dr. Michael Mbagwu, an ophthalmologist and Verana’s Senior Medical Director. Verana partners with the American Academy of Ophthalmology, the American Academy of Neurology and the American Urologic Association to manage their clinical registries which were built to improve quality of care, answer research questions and help physicians report quality metrics. Join host Michael Carrese for an exploration of the ways medicine is being changed by the ever-growing amount of data available and the new technologies which allow clinicians and others to analyze and use all of that information. “Some of the things that we just assumed were never possible or were kind of hopeless endeavors are now possible for the first time thanks to AI.” 

Mentioned in this episode: https://www.veranahealth.com/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We've heard many stories on Raise the Line about patients and their family members who, upon getting a rare disease diagnosis, build a non-profit organization from scratch to boost advocacy and research for the condition in question. This is obviously a pretty big hill to climb for people with no background in such things. Well, today we're going to learn about Beacon for Rare Diseases, a UK non-profit designed to provide the expertise and support needed to get a rare disease patient group off the ground, and to connect these groups with each other for the purpose of mutual education and support. “What we've seen is that people forming and building patient organizations can help really trigger a new community around that, and help drive the field forward,” Beacon CEO Dr. Rick Thompson tells host Shiv Gaglani. “What we want to do as an organization is help those patient groups form, to grow, and to professionalize their work.” Tune in to find out how Dr. Thompson’s background in evolutionary biology, research and education impacts his work at Beacon, why rare diseases should be approached in the same way as cancer, and his interest in repurposing existing drugs for use in treating rare diseases. 

Mentioned in this episode:  https://www.rarebeacon.org/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“It is my deepest wish for all of my students to find me as a mentor and a coach,” says Beth Hendricks, RN, MSN and assistant professor at New Mexico State University School of Nursing. That can be traced back in part to a nursing educator early in her career who took that approach and built her confidence. Being devoted to paying that forward is one reason Hendricks is the winner of the 2022 Osmosis Raise The Line Faculty Awards in the RN-Nurse Practitioner category. Her student nominators describe her as both empathetic and driven to see them succeed, which is a deliberate balance Hendricks tries to strike. “Having their backs but also challenging them is the best method for connecting with students,” she tells host Michael Carrese. Check out this insightful conversation on how to motivate students to fight through “imposter syndrome,” the importance of learning to think like a nurse, and why she encourages students to find their unique learning style among many other tips for educators. 

Mentioned in this episode: www.osmosis.org/faculty-awards

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We've learned quite a bit on Raise the Line about at-home monitoring technology for chronic disease management, but on this episode we're going to explore the use of tech for a different aspect of the patient experience: post-surgical care. It’s a significant issue because hospitals are incentivized to discharge patients as soon as possible, leaving many to recover at home with varying degrees of support. “The whole postoperative period is a huge black box of missing information. We really don't know how patients are doing after their surgery because we’re not capturing the 24-7 experience the patient is living through,” says Dr. Sanjeev Suratwala, an orthopedic spine surgeon who co-founded Recuperet Health to fill that information gap. He tapped software engineer and management consultant Gary Arora to develop Recuperet’s technology platform with the aim of keeping it simple for users. “You simply log in with your credentials. It's like watching Netflix on your browser. You don't need to download or install anything,” he tells host Michael Carrese. Patients wear Fitbits that track vital signs, and the system is designed to send alerts to providers -- and a patient-designated caretaker - if something seems concerning.  Tune in to learn how Recuperet is leveraging AI and gamification as part of its approach, and how this solution can be broadened to other specialties beyond orthopedics. 

Mentioned in this episode: https://recuperet.io

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“I noticed early on in my academic career that the traditional methods of engagement and the lecture was no longer working for millennials and Gen Z, which is the first generation to completely grow up being immersed in technology,” says Dr. Nicolene “Nikki” Lottering of Bond University in Queensland. That set the assistant professor of anatomy and forensic anthropologist on the path of determining how to use technology effectively without going too far. “For me, it's about the responsible use of technology to meet students halfway and harness that power to engage them and make them excited about what they're learning.” This thoughtful approach is one of the reasons Lottering is the winner of the 2022 Osmosis Raise the Line Faculty Award in the Anatomy and Physiology category. Another, according to her student nominators, is her compassion for her students. This became particularly pronounced during COVID which presented enormous challenges to educators and students alike. “I believe good education comes from a place of genuinely caring about your students,” she tells host Michael Carrese. “We can learn as a community and we can, through learning, find coping strategies as well. It's not always about the content, but it's actually about the community.” Don’t miss this inspiring conversation from an educator with many insights on how to connect students to their learning and to each other. 

Mentioned in this episode: www.Osmosis.org/faculty-awards

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Perhaps the most noteworthy element of Osmosis from Elsevier’s Year of the Zebra educational initiative is the new, open-access, peer-reviewed journal Rare. Open Research in Rare Diseases.It joins Elsevier's leading collection of 2,500 publications in science and medicine. Rare is an open journal in multiple senses because, in an unusual step, contributions are being welcomed from patients as well as scientists. “We need the patient's voice to find out what their needs and challenges are every day,” says editor-in-chief, Dr. Wendy van Zelst-Stams. “We really want to have both a clinical impact on rare disease patients and an impact on their well-being in daily life.” Dr. van Zelst-Stams is taking on this new role in addition to her work leading the Clinical Genetics Section in the Department of Human Genetics of the Radboud University Medical Center and the Dutch Society of Clinical Genetics. In this enlightening conversation with host Shiv Gaglani, you’ll learn about Europe’s efforts to improve care for rare disease patients, the “DNA-first” approach her program takes to reduce the diagnostic odyssey, and the types of content that will be featured in this multidisciplinary scientific journal. 

Mentioned in this episode: https://www.sciencedirect.com/journal/rare

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast